Get the Stockscreener App
55.82
22.96%
-16.64
Globus Medical Inc stock is traded at $55.82, with a volume of 10.89M.
It is down -22.96% in the last 24 hours and down -24.85% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$72.46
Open:
$60.97
24h Volume:
10.89M
Relative Volume:
7.70
Market Cap:
$9.89B
Revenue:
$2.48B
Net Income/Loss:
$91.51M
P/E Ratio:
83.31
EPS:
0.67
Net Cash Flow:
$293.77M
1W Performance:
-22.38%
1M Performance:
-24.85%
6M Performance:
-30.98%
1Y Performance:
-13.27%
1-Day Range:
$54.48
$61.50
1-Week Range:
$54.48
$73.05
52-Week Range:
$54.48
$94.93
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
55.82 | 9.89B | 2.48B | 91.51M | 293.77M | 0.67 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Globus medical outlines $2.8B-$2.9B 2025 revenue guidance amid Nevro integration - MSN
Globus Medical (GMED) Stock Plummets After Q1 Earnings Miss - GuruFocus
Globus Medical stock target cut to $78 by Oppenheimer - Investing.com Canada
Globus closes down 23% as earnings misses, lowered EPS guidance weigh (GMED:NYSE) - Seeking Alpha
A Glimpse Into The Expert Outlook On Globus Medical Through 6 Analysts - Benzinga
Truist cuts Globus Medical stock target to $68, maintains hold By Investing.com - Investing.com Canada
Globus Medical (GMED) Price Target Reduced by Stifel | GMED Stock News - GuruFocus
Globus Medical (GMED) Price Target Lowered to $80 by Piper Sandler | GMED Stock News - GuruFocus
Globus Medical (GMED) Target Price Adjusted by RBC Capital | GMED Stock News - GuruFocus
Truist Securities Adjusts Globus Medical Price Target to $68 From $80, Maintains Hold Rating - marketscreener.com
Globus Medical (GMED) Faces Price Target Reduction Amid Q1 Strug - GuruFocus
Globus Medical (GMED) Sees Price Target Cut Amid Q1 Challenges | GMED Stock News - GuruFocus
Globus Medical (GMED) Faces Price Target Reduction Amid Q1 Challenges | GMED Stock News - GuruFocus
Globus Medical sales decrease 1.4% to USD 598.1M in Q1 2025 - Medical Buyer
Globus Medical Reports Mixed Q1 2025 Results, Sets Positive Revenue GuidanceNews and Statistics - IndexBox
Globus Medical Reports Q1 2025 Financial Results - TipRanks
Globus Medical Inc (GMED) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Globus Medical: Q1 Earnings Snapshot - Norwalk Hour
Globus Medical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Globus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates - Yahoo Finance
GLOBUS MEDICAL INC SEC 10-Q Report - TradingView
Globus Medical Inc Q1 2025 Earnings: EPS of $0.54 Misses Estimat - GuruFocus
Globus Medical Reports First Quarter 2025 Results | GMED Stock N - GuruFocus
Globus Medical (NYSE:GMED) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops 17.1% - Yahoo Finance
Globus Medical Q1 Non-GAAP Earnings Rise, Sales Decline -- Shares Fall After Hours - marketscreener.com
Globus Medical Reports First Quarter 2025 Results | GMED Stock News - GuruFocus
Globus Medical Inc Q1 2025 Earnings: EPS of $0.54 Misses Estimates, Revenue at $598.1 Million Falls Short - GuruFocus
Globus Medical Reports First Quarter 2025 Results - GlobeNewswire
Earnings To Watch: Globus Medical (GMED) Reports Q1 Results Tomorrow - Yahoo Finance
What Does Globus Medical, Inc.'s (NYSE:GMED) Share Price Indicate? - Yahoo Finance
At US$71.91, Is It Time To Put Globus Medical, Inc. (NYSE:GMED) On Your Watch List? - simplywall.st
Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance
Interspinous Spacers Market Analysis: Data-Driven Insights - openPR.com
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates - TradingView
BlackRock, Inc. Adjusts Stake in Globus Medical Inc - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
What Does the Market Think About Globus Medical?Globus Medical (NYSE:GMED) - Benzinga
Globus Medical (GMED): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Globus Medical (GMED): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com
Globus Medical: Digesting Another Acquisition (NYSE:GMED) - Seeking Alpha
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term - Yahoo
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock? - TradingView
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much TodayGlobus Medical (NYSE:GMED) - Benzinga
Globus Medical to Announce Q1 2025 Results and Host Investor Call - MSN
Robotic-assisted Surgery Systems Market Future Business - openPR.com
Impingement Syndrome Market Future Business Opportunities - openPR.com
International Growth Drives GMED Stock Amid Fierce Competition - MSN
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 38% Undervalued - simplywall.st
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):